Oxilan (ioxilan) dosing, indications, interactions, adverse effects, and more

Sections

Sections ioxilan
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

300mgI/mL (62%)
350mgI/mL (73%)

CECT Imaging

CECT of Head

30-60 g iodine indicated
Oxilan 300: 100-200 mL IV
Oxilan 350: 86-172 mL IV
Not to exceed 200 mL

CECT of Body

15-60 g iodine indicated
Oxilan 300: 50-200 mL IV
Oxilan 350: 43-172 mL IV
Not to exceed 200 mL

Cerebral Arteriography

8-12 mL intra-arterially (2.4-3.6 g iodine); not to exceed 150 mL

Intra-arterial administration

Oxilan 350 is indicated
Left and right coronary arteries: 2-10 mL (0.7-3.5 g iodine)
Left ventricle: 25-50 mL (8.75-17.5 g iodine)

Safety and efficacy not established

Frequency Not Defined

Erythema

Pruritus

Urticaria

Skin discoloration

Stevens-Johnson syndrome

Toxic epidermal necrolysis (SJS/TEN)

Acute generalized exanthematous pustulosis (AGEP)

Drug reaction with eosinophilia and systemic symptoms (DRESS)

Black Box Warning

The reaction to intrathecal administration can be fatal

Contraindications

Hypersensitivity to product or components

Intrathecal administration (potentially fatal)

Cautions

Caution in severe renal impairment, combined renal/hepatic disease, thyroid dysfunction, multiple myeloma, anuria, pheochromocytoma, sickle cell, CHF, severe arterial/venous disease

Severe cutaneous adverse reactions(SCAR), including Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS), may develop from 1 hr to several weeks after intravascular contrast agent administration; reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions; avoid administering product to patients with history of severe cutaneous adverse reaction to product

May cause renal failure in patients with advanced vascular disease, diabetes; should be well hydrated before/after procedure

Hypersensitivity to contrast medium, iodine

Myocardial infarctions and stroke reported with angiographic procedures

Avoid extravasation, especially in patients with severe arterial or venous disease

Inhibits blood coagulation (less than ionic contrast media in vitro)

Allergies (bronchial asthma, hay fever, food allergies)

Pregnancy & Lactation

Pregnancy Category: B

Lactation: Not known, use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Opacifies vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures until significant hemodilution occurs

Pharmacokinetics

Vd: 7-10 L

Excretion: Urine (93.7%); bile/feces (negligible)

Half-life: 137 min (men); 102 min (women)

Protein binding: Negligible

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]